Pirfenidone Medications

Pirfenidone Info

What is Pirfenidone?

Pirfenidone is an oral medication that belongs to the class of anti-fibrotic agents. Its main purpose is to slow the formation of scar tissue in the lungs. In the United Kingdom, pirfenidone is available under the brand name Esbriet and is approved by the Medicines and Healthcare products Regulatory Agency (MHRA).

Medications that Contain Pirfenidone

The primary product that contains pirfenidone in the UK market is Esbriet. It is supplied as film-coated tablets in several strengths, allowing doctors to tailor the dose to each patient’s needs. Both the generic name (pirfenidone) and the brand name appear on prescription labels, so patients may encounter either term in pharmacy records. Esbriet is the only MHRA-licensed preparation that contains this active ingredient.

Conditions Pirfenidone Treats

• Idiopathic Pulmonary Fibrosis (IPF) - a chronic lung disease where the tissue becomes thickened and stiff, making breathing difficult. Pirfenidone helps to slow the decline in lung function.
• Progressive Fibrosing Interstitial Lung Diseases - some forms of lung scarring that behave similarly to IPF may also be managed with pirfenidone, depending on a clinician’s assessment.
• Research Settings - the drug is being studied for other fibrotic conditions, but its use outside the above indications remains experimental in the UK.

These conditions are typically managed by respiratory specialists who consider the patient’s overall health and lung function before recommending therapy.

How Pirfenidone Works

Pirfenidone interferes with processes that lead to excess collagen production in the lungs. By reducing this abnormal tissue growth, the drug helps keep the airways more flexible. Most people notice a gradual effect, with improvements in the rate of lung-function decline becoming apparent over weeks to months rather than instantly.

Safety and Side Effects

Common Side Effects

• Nausea or upset stomach, often mild and transient.
• Loss of appetite, which may lead to temporary weight changes.
• Skin rash or mild itching, especially after the first few weeks of treatment.
• Tiredness or headache, generally manageable with rest.

These reactions are typical of many oral medicines and usually lessen as the body adjusts.

Serious Reactions

• Severe allergic response - swelling of the face, lips, tongue, or difficulty breathing. Seek emergency care if these signs appear.
• Liver concerns - unusual yellowing of the skin or eyes, dark urine, or persistent fatigue may indicate liver involvement. Prompt medical attention is required.
• Significant rash or blistering - extensive skin reactions should be reported immediately.

Who Should Be Cautious

• People with known liver disease or impaired liver function need careful monitoring.
• Individuals who have previously reacted adversely to pirfenidone or any of its ingredients should avoid the medication.
• Pregnant or breastfeeding women are advised not to use pirfenidone unless a specialist determines the benefit outweighs the risk.

Interaction Awareness

• Alcohol - drinking large amounts can increase the risk of liver problems.
• Certain antibiotics and antifungal agents - some may affect how pirfenidone is processed in the body.
• Smoking - continues to harm lung health and may diminish the overall benefit of treatment.
• For a complete list of possible interactions, refer to the specific product information for Esbriet.

Important Things to Remember

Store Esbriet tablets in a cool, dry place away from direct sunlight. The medication is usually taken for an extended period, often many months or years, depending on the underlying condition. While the active ingredient is the same across all Esbriet tablets, strengths differ, so always follow the instructions that accompany your specific supply. For detailed usage, dosing, administration, refer to your specific medication's information.

Key Terms

Idiopathic Pulmonary Fibrosis: A disease where lung tissue becomes scarred without a known cause, leading to progressive breathing difficulties.

Fibrosis: The formation of excess fibrous connective tissue as part of a healing or disease process.

Information Disclaimer

This article offers general educational information about pirfenidone as an active substance used in various medicines. Its purpose is to help patients better understand the ingredient and the conditions it is used to treat. It is not a substitute for professional medical advice or for the specific instructions provided with individual products. Medicines containing pirfenidone may differ in formulation, strength, and directions for use. Always consult the labeling of your particular medication and follow your healthcare provider’s guidance for complete information on proper use, dosage, and safety.